Table 2.
Incidence rates of genital HPV infection among men in the HIM Study (N=4032).
| Ages 18–24
|
Ages 25–34
|
Ages 35–44
|
Ages 45–54
|
Ages 55–70
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. Infec- tions |
Incidence Rate (95% CI)a |
No. Infec- tions |
Incidence Rate (95% CI)a |
IRRb(95% CI)a | No. Infec- tions |
Incidence Rate (95% CI)a |
IRRb(95% CI)a | No. Infec- tions |
Incidence Rate (95% CI)a |
IRRb(95% CI)a | No. Infec- tions |
Incidence Rate (95% CI)a |
IRRb(95% CI)a | |
| Any HPV | 412 | 30.7 (27.8–33.8) | 350 | 30.5 (27.4–33.8) | 0.99 (0.86–1.15) | 324 | 29.5 (26.4–32.9) | 0.96 (0.83–1.11) | 102 | 25.4 (20.7–30.8) | 0.83 (0.67–1.03) | 50 | 23.9 (17.8–31.5) | 0.78 (0.58–1.04) |
| HR HPV | 421 | 19.6 (17.8–21.6) | 404 | 17.7 (16.0–19.6) | 0.90 (0.79–1.04) | 377 | 16.2 (14.6–17.9) | 0.83 (0.72–0.95) | 124 | 16.1 (13.4–19.1) | 0.82 (0.67–1.00) | 51 | 13.9 (10.3–18.2) | 0.71 (0.53–0.95) |
| HPV 16 | 183 | 5.0 (4.3–5.8) | 176 | 4.0 (3.5–4.7) | 0.80 (0.65–0.98) | 120 | 3.0 (2.5–3.6) | 0.60 (0.48–0.76) | 43 | 3.3 (2.4–4.4) | 0.66 (0.47–0.92) | 19 | 2.7 (1.6–4.3) | 0.54 (0.34–0.87) |
| HPV 18 | 91 | 2.2 (1.8–2.7) | 95 | 1.9 (1.6–2.4) | 0.86 (0.65–1.15) | 49 | 1.1 (0.8–1.4) | 0.50 (0.35–0.71) | 22 | 1.5 (1.0–2.3) | 0.68 (0.43–1.09) | 8 | 1.1 (0.5–2.2) | 0.50 (0.24–1.03) |
| HPV 31 | 68 | 1.6 (1.2–2.0) | 66 | 1.3 (1.0–1.7) | 0.81 (0.58–1.14) | 44 | 1.0 (0.7–1.3) | 0.63 (0.43–0.91) | 13 | 0.9 (0.5–1.5) | 0.56 (0.31–1.02) | 8 | 1.1 (0.5–2.1) | 0.69 (0.33–1.43) |
| HPV 33 | 21 | 0.5 (0.3–0.7) | 18 | 0.4 (0.2–0.6) | 0.80 (0.43–1.50) | 16 | 0.4 (0.2–0.6) | 0.80 (0.42–1.53) | 7 | 0.5 (0.2–1.0) | 1.00 (0.43–2.35) | 2 | 0.3 (0.0–0.9) | 0.60 (0.14–2.56) |
| HPV 39 | 128 | 3.2 (2.7–3.8) | 96 | 2.0 (1.6–2.5) | 0.63 (0.48–0.81) | 64 | 1.5 (1.2–1.9) | 0.47 (0.35–0.63) | 21 | 1.5 (0.9–2.2) | 0.47 (0.30–0.74) | 9 | 1.3 (0.6–2.4) | 0.41 (0.21–0.80) |
| HPV 45 | 66 | 1.5 (1.2–1.9) | 84 | 1.7 (1.4–2.1) | 1.13 (0.82–1.56) | 79 | 1.8 (1.4–2.3) | 1.20 (0.87–1.66) | 21 | 1.5 (0.9–2.2) | 1.00 (0.61–1.63) | 5 | 0.7 (0.2–1.6) | 0.47 (0.19–1.16) |
| HPV 51 | 208 | 5.7 (4.9–6.5) | 159 | 3.6 (3.0–4.1) | 0.63 (0.51–0.78) | 130 | 3.2 (2.7–3.8) | 0.56 (0.45–0.70) | 41 | 3.0 (2.2–4.1) | 0.53 (0.38–0.74) | 16 | 2.4 (1.3–3.8) | 0.42 (0.25–0.70) |
| HPV 52 | 131 | 3.3 (2.7–3.9) | 122 | 2.6 (2.1–3.1) | 0.79 (0.62–1.01) | 101 | 2.4 (2.0–2.9) | 0.73 (0.56–0.94) | 34 | 2.4 (1.7–3.4) | 0.73 (0.50–1.06) | 17 | 2.6 (1.5–4.1) | 0.79 (0.48–1.31) |
| HPV 58 | 82 | 1.9 (1.5–2.4) | 66 | 1.4 (1.0–1.7) | 0.74 (0.53–1.02) | 54 | 1.2 (0.9–1.6) | 0.63 (0.45–0.89) | 23 | 1.6 (1.0–2.4) | 0.84 (0.53–1.34) | 7 | 1.0 (0.4–2.0) | 0.53 (0.24–1.14) |
| HPV 59 | 168 | 4.4 (3.8–5.1) | 142 | 3.1 (2.6–3.7) | 0.70 (0.56–0.88) | 99 | 2.4 (1.9–2.9) | 0.55 (0.43–0.70) | 36 | 2.7 (1.9–3.7) | 0.61 (0.43–0.88) | 16 | 2.4 (1.3–3.8) | 0.55 (0.33–0.91) |
| LR HPV | 443 | 24.2 (22.0–26.5) | 396 | 24.5 (22.1–27.0) | 1.01 (0.88–1.16) | 324 | 21.4 (19.1–23.8) | 0.88 (0.77–1.02) | 111 | 20.5 (16.9–24.7) | 0.85 (0.69–1.04) | 54 | 17.9 (13.4–23.3) | 0.74 (0.56–0.98) |
| HPV 6 | 142 | 3.7 (3.1–4.4) | 163 | 3.7 (3.2–4.3) | 1.00 (0.80–1.25) | 98 | 2.4 (1.9–2.9) | 0.65 (0.50–0.84) | 26 | 1.9 (1.3–2.8) | 0.51 (0.34–0.78) | 15 | 2.1 (1.2–3.5) | 0.57 (0.33–0.97) |
| HPV 11 | 40 | 0.9 (0.7–1.3) | 56 | 1.1 (0.8–1.5) | 1.22 (0.81–1.83) | 37 | 0.8 (0.6–1.1) | 0.89 (0.57–1.39) | 6 | 0.4 (0.1–0.9) | 0.44 (0.19–1.05) | 6 | 0.8 (0.3–1.8) | 0.89 (0.38–2.10) |
| HPV 53 | 146 | 3.7 (3.1–4.3) | 174 | 3.9 (3.4–4.5) | 1.05 (0.85–1.31) | 112 | 2.7 (2.3–3.3) | 0.73 (0.57–0.93) | 44 | 3.4 (2.4–4.5) | 0.92 (0.66–1.29) | 23 | 3.6 (2.3–5.4) | 0.97 (0.63–1.51) |
| HPV 61 | 90 | 2.2 (1.7–2.7) | 147 | 3.2 (2.7–3.8) | 1.45 (1.12–1.89) | 124 | 3.0 (2.5–3.6) | 1.36 (1.04–1.79) | 43 | 3.2 (2.3–4.2) | 1.45 (1.01–2.09) | 17 | 2.5 (1.4–4.0) | 1.14 (0.68–1.91) |
| HPV 62 | 164 | 4.2 (3.6–4.9) | 164 | 3.7 (3.2–4.4) | 0.88 (0.71–1.09) | 149 | 3.9 (3.3–4.6) | 0.93 (0.74–1.16) | 49 | 3.9 (2.9–5.1) | 0.93 (0.67–1.28) | 26 | 4.3 (2.8–6.3) | 1.02 (0.68–1.55) |
| HPV 66 | 160 | 4.1 (3.5–4.8) | 144 | 3.1 (2.6–3.7) | 0.76 (0.60–0.95) | 113 | 2.7 (2.2–3.3) | 0.66 (0.52–0.84) | 29 | 2.1 (1.4–3.1) | 0.51 (0.34–0.76) | 15 | 2.2 (1.2–3.5) | 0.54 (0.32–0.91) |
| HPV 84 | 226 | 6.3 (5.5–7.2) | 172 | 4.0 (3.4–4.6) | 0.63 (0.52–0.77) | 128 | 3.3 (2.7–3.9) | 0.52 (0.42–0.65) | 55 | 4.3 (3.2–5.6) | 0.68 (0.51–0.92) | 23 | 3.6 (2.3–5.4) | 0.57 (0.37–0.88) |
| HPV 89c | 223 | 5.9 (5.2–6.7) | 173 | 3.9 (3.4–4.6) | 0.66 (0.54–0.81) | 140 | 3.5 (3.0–4.2) | 0.59 (0.48–0.73) | 49 | 3.7 (2.7–4.9) | 0.63 (0.46–0.85) | 18 | 2.6 (1.6–4.2) | 0.44 (0.27–0.71) |
| HPV 9vd | 359 | 14.1 (12.7–15.7) | 378 | 13.4 (12.0–14.8) | 0.95 (0.82–1.10) | 310 | 11.2 (10.0–12.5) | 0.79 (0.68–0.92) | 108 | 11.8 (9.7–14.2) | 0.84 (0.67–1.04) | 53 | 10.7 (8.0– | 0.76 (0.57–1.01) |
Note: HR: high-risk, LR: low risk, IRR: incidence rate ratio, CI: confidence interval. Although 37 high- and low-risk HPV types are evaluated using the Roche Linear Array method, data are only shown for individual types included in the 9-valent HPV vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) and those that had incidence rates > 3.0 in any age group.
a
Incidence rate is estimated as the number of cases per 1000 person-months.
b
IRRs were calculated using 18–24 years as the referent age group, with significant values indicated in bold.
c
Formerly HPV CP 6108.
d
One or more of the 9-valent HPV vaccine types.